An ongoing phase I/II trial in CD19+ B-cell lymphomas is exploring allogeneic, cord blood-derived CD19-specific CAR NKs, co-expressing IL15 (NCT03056339) [517]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.